ANI PHARMACEUTICALS INC
ANI Pharmaceuticals develops, manufactures and commercializes therapeutics through its Rare Disease, Generics and Brands businesses. Its portfolio includes more than 120 generic products, branded medicines, and rare disease and ophthalmology products. These include Purified Cortrophin Gel, ILUVIEN and YUTIQ, as well as Atacand, Arimidex, Inderal LA and other branded products. ANI markets ILUVIEN in the U.S. for diabetic macular edema and chronic non-infectious uveitis affecting the posterior segment of the eye. It sells products through its commercial operations and, for some products, specialty pharmacy networks and partnerships. ANI earns money by marketing and selling pharmaceutical products developed internally or obtained through acquisitions, product rights and distribution agreements. It owns and operates three pharmaceutical manufacturing facilities, in Baudette, Minnesota, and East Windsor, New Jersey, and also uses third-party manufacturers for certain products. ANI is headquartered in Princeton, New Jersey.
Reads like this one publish minutes after the filing lands on EDGAR. Get them as JSON over the API or inside your AI agent over MCP.
ANI PHARMACEUTICALS INC (ANIP) filed an SEC Form 8-K — Entry into a Material Definitive Agreement. Exhibit 99.1 STRICTLY CONFIDENTIAL To: ANI Pharmaceuticals, Inc., corporate identity number 3379943, domiciled in Delaware, 104 Carnegie Center Drive, Suite 300, Princeton, New Jersey 08540 USA (the “ Offeror ”) Re: Irrevocable undertaking in relation to the public offer for Eget
ANI Pharmaceuticals reported 3Q 2026 revenue of $290.78M, up 27.6% YoY, and net income of $35.15M, up 32.1% YoY. Growth was driven by Rare Disease and Brands, including Cortrophin Gel and ILUVIEN, as well as higher generic product sales. Brands portfolio revenue declined 6.5%.
ANI PHARMACEUTICALS INC (ANIP) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 ANI Pharmaceuticals Reports Third Quarter 2026 Financial Results • Quarterly net revenues of $290.8 million, an increase of 27.6% year-over-year • Pu rified Cortrophin ® Gel net revenues of $138.7 million, an increase of 36.1% year-over-year • Quarterly GAAP net inco
Over the past 7 days, AlphAI's AI scored 15 news stories mentioning ANIP (ANI PHARMACEUTICALS INC). Coverage has skewed bullish: 10 bullish, 5 neutral, and 0 bearish.
Recent ANIP coverage spans earnings, corporate actions and mergers & acquisitions.
In the last 30 days, ANIP insiders filed 3 SEC Form 4 transactions — no purchases and 3 sales ($633K). The most active reporter was Cook Meredith, SR. VP, GENERAL COUNSEL & SEC., with 1 filing. 100% of those filings were made under pre-arranged Rule 10b5-1 plans.
The announced takeover could drive ANIP stock higher if the market views the deal as accretive, but uncertainty around regulatory approval and financing may create volatility.
Earnings beat on both revenue and EPS suggests upside pressure on the stock.
ANI delivered strong Q3 earnings, updated adjusted EBITDA guidance and announced a strategic acquisition, suggesting near‑term upside.
Strong earnings beat and a sizable acquisition offer could boost ANI's stock.
ANI stock likely to rise as the market prices in the acquisition premium; Egetis shares expected to jump on the offer.
AlphAI scores every news story that mentions ANIP with an AI model for sentiment and relevance, and aggregates insider trades from ANI PHARMACEUTICALS INC's SEC EDGAR Form 4 filings. Figures refresh continuously.
ANI PHARMACEUTICALS INC (ANIP) filed an SEC Form 8-K — Entry into a Material Definitive Agreement. Exhibit 99.1 STRICTLY CONFIDENTIAL To: ANI Pharmaceuticals, Inc., corporate identity number 3379943, domiciled in Delaware, 104 Carnegie Center Drive, Suite 300, Princeton, New Jersey 08540 USA (the “ Offeror ”) Re: Irrevocable undertaking in relation to the public offer for Eget
ANI Pharmaceuticals reported 3Q 2026 revenue of $290.78M, up 27.6% YoY, and net income of $35.15M, up 32.1% YoY. Growth was driven by Rare Disease and Brands, including Cortrophin Gel and ILUVIEN, as well as higher generic product sales. Brands portfolio revenue declined 6.5%.
ANI PHARMACEUTICALS INC (ANIP) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 ANI Pharmaceuticals Reports Third Quarter 2026 Financial Results • Quarterly net revenues of $290.8 million, an increase of 27.6% year-over-year • Pu rified Cortrophin ® Gel net revenues of $138.7 million, an increase of 36.1% year-over-year • Quarterly GAAP net inco
ANI Pharmaceuticals reported Q3 2026 net revenue of $290.8M, up 27.6% YoY. Cortrophin Gel revenue grew 36.1% to $138.7M. The company raised guidance and announced a $560M offer to acquire Egetis Therapeutics, expanding its rare disease portfolio. ANI also repurchased $20M in stock YTD.
ANI Pharmaceuticals (ANIP) offers $560M to acquire Egetis Therapeutics, a rare disease drug company. Egetis' lead drug, EMCITATE®, treats a rare genetic disorder and has peak sales potential of over $300M. The deal values Egetis at SEK 5.6B, a 27% premium. ANI's board and major shareholders support the acquisition, which is subject to regulatory approvals and shareholder acceptance.
ANI Pharmaceuticals (ANIP) reports Q3 earnings Thursday. Last quarter, revenue grew 25.9% YoY to $266M, beating estimates but missing full-year guidance. Analysts expect 22.3% YoY revenue growth this quarter. ANIP stock is unchanged in the last month, with an average price target of $105.78.
ANI Pharmaceuticals (Nasdaq: ANIP) will release its Q3 2026 financial results on Nov. 5, 2026, at 8:00 a.m. ET. The company will host a webcast and conference call to discuss the results, led by its CEO, CFO, and Head of Rare Disease. The live and archived webcast will be available on the company's website.
Viatris (VTRS), Amphastar (AMPH), ANI Pharmaceuticals (ANIP), and Amneal (AMRX) reported Q2 earnings. VTRS revenue grew 4.9% YoY, beating estimates. AMPH saw 5.4% growth, ANIP 25.9%, and AMRX 9.9%. Stocks reacted positively except ANIP, which fell 12%.
ANI Pharmaceuticals (ANIP) launched a generic version of Duloxetine Delayed-Release Capsules, a widely used medicine with about $247 million in annual U.S. sales. The company aims to provide stable supply and expand its product offerings, according to CEO Nikhil Lalwani.
Bristol-Myers Squibb (BMY) reported Q2 revenue of $12.97B, up 5.7% YoY, beating estimates. Zoetis (ZTS) reported flat revenue of $2.47B, missing estimates. Merck (MRK) reported $16.61B revenue, up 5.1% YoY, beating estimates. ANI Pharmaceuticals (ANIP) reported $266M revenue, up 25.9% YoY, with mixed results. Stocks reacted variably post-earnings.
